Tecnología inicial en el estudio de diabetes tipo 1 en riesgo (STAR-T1D)
Estudio de tecnología inicial en diabetes tipo 1 en riesgo (STAR-T1D)
Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c ≥8.0%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Estelle M Everett, MD, MHS
- Número de teléfono: 310-267-0625
- Correo electrónico: eeverett@mednet.ucla.edu
Ubicaciones de estudio
-
-
California
-
Santa Monica, California, Estados Unidos, 90404
- Reclutamiento
- UCLA
-
Contacto:
- Rebecca Lopez, BA
- Número de teléfono: (310) 882-0033
- Correo electrónico: rebeccalopez@mednet.ucla.edu
-
Contacto:
- Erin E Shaw, B.S.
- Correo electrónico: EEShaw@mednet.ucla.edu
-
Sylmar, California, Estados Unidos, 91342
- Reclutamiento
- Olive View-UCLA Medical Center
-
Contacto:
- Hugo Torres, MD
- Número de teléfono: 747-210-3000
- Correo electrónico: HATorres@mednet.ucla.edu
-
Torrance, California, Estados Unidos, 90502
- Reclutamiento
- Harbor-UCLA Medical Center
-
Contacto:
- Joyce A Graham
- Número de teléfono: (310) 222-1870
- Correo electrónico: jgraham@lundquist.org
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Type 1 Diabetes
- A1c ≥ 8.0%
- Not insulin pump user
- Primary language of English or Spanish
- Have medical insurance coverage
Exclusion Criteria:
- No measured A1c in the past year
- Have comorbidities that can result in inaccurate hemoglobin A1c
- Have cognitive, physical or mental impairment precluding diabetes technology use
- Limited life expectancy (<1 year)
- Pregnancy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Hybrid Closed Loop Insulin Pump System
Participants will meet 1:1 with our CDE for at least 6 sessions over 6 weeks. Sessions will cover self-management basics, carb counting, CGM interpretation, hypoglycemia and hyperglycemia management and troubleshooting device issues. The investigators will follow up with participants in 24 and 72 hours after CGM and insulin pump initiation, respectively, to answer any device related questions that may arise in between sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects and evaluate device and safety issues associated with pump settings in the HCL arm. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
Patients will be started on an automated insulin delivery system. |
|
Sin intervención: Control
Participants in the control arm will receive diabetes education at a similar frequency as the intervention group. Diabetes education for the control group will be a combination of in-person visits with the CDE and telephone brief diabetes education sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of screened participants that are eligible
Periodo de tiempo: 6 months
|
Eligible among screened, enrolled among eligible, excluded among screened (and why) based on screening, recruitment and enrollment data. |
6 months
|
|
Proportion of enrolled participants that are randomized
Periodo de tiempo: 6 months
|
Randomized among enrolled, and receiving allocated intervention among randomized. |
6 months
|
|
Proportion of average time delay to enrollment
Periodo de tiempo: 6 months
|
Average time delay from screening to enrollment. |
6 months
|
|
Proportion of retention among participants randomized to the Intervention Group
Periodo de tiempo: 6 months
|
Retention among participants receiving allocated intervention after being randomized and discontinued intervention among randomized. |
6 months
|
|
Proportion of retention among participants randomized
Periodo de tiempo: 6 months
|
Participants lost to follow-up among those initially randomized. |
6 months
|
|
Proportion of retention among participants randomized
Periodo de tiempo: 6 months
|
Retention rates by participants completing all research assessments among randomized. |
6 months
|
|
Number of participants who adhere to assigned treatment
Periodo de tiempo: 6 months
|
Treatment-specific adherence, Adherence to study protocol and Proportion of planned assessments that are completed. Fidelity, which pertains to guaranteeing that the intervention is delivered in accordance with the established protocol, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. Adherence, which relates to the extent to which participants follow the treatment and study protocol, as well as the proportion of planned assessments completed, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. |
6 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in A1c
Periodo de tiempo: 6 months
|
Serum Hemoglobin A1c laboratory measurement |
6 months
|
|
Episodes and % of time with severe hypoglycemia ( BG <54 mg/dl)
Periodo de tiempo: 6 months
|
Hypoglycemia will be measure by combining CGM metrics and glucometer to report severe hypoglycemia in mg/dl. |
6 months
|
|
Mean Diabetes Ketoacidosis Episodes Incidence
Periodo de tiempo: 6 months
|
Assess instances of diabetic ketoacidosis through participant surveys and comprehensive chart reviews. |
6 months
|
|
ED visits/Hospitalizations Number of diabetes related ED visits or hospitalizations
Periodo de tiempo: 6 months
|
Number of diabetes related ED visits or hospitalizations |
6 months
|
|
Treatment Burden and Satisfaction: Diabetes Distress
Periodo de tiempo: 6 months
|
Assessing treatment burden through the Type 1 Diabetes Distress Assessment System T1DDAS, which comprises eight questions and evaluates ten prevalent sources of diabetes distress in adults with type 1 diabetes. The score indicates the level of diabetes distress reported by the respondent, with higher scores indicating greater intensity. The core scale scoring ranges 1 to 5. This scale assesses each of ten common Sources of diabetes distress for adults with type 1 diabetes: Financial Worries, Interpersonal Challenges, Management Difficulties, Shame, Hypoglycemia Concerns, Healthcare Quality, Lack Of Diabetes Resources, Technology Challenges, Burden To Others, Worries About Complications. The higher the score, the more impactful that Source is likely to be in contributing to diabetes distress for this individual with the minimum value being 1 and maximum value being 5. |
6 months
|
|
Treatment Burden and Satisfaction: Insulin Treatment Satisfaction
Periodo de tiempo: 6 months
|
Assessed treatment burden and satisfaction using the Insulin Treatment Satisfaction Questionnaire (ITSQ), consisting of 22 questions among 5 content clusters with a score from 0 to 100% where a higher score indicates greater satisfaction with insulin treatment. The scale explores perceptions of current insulin treatment and its impact on daily life. |
6 months
|
|
Treatment Burden and Satisfaction: Glucose Monitoring System Satisfaction (GMSS)
Periodo de tiempo: 6 months
|
Examined treatment burden and satisfaction employing the Glucose Monitoring System Satisfaction Survey (GMSS), comprising 15 questions divided into four subcategories: openness, emotional burden, behavioral burden and trust. Higher scores within each subcategory denote either greater satisfaction or burden, depending on the specific aspect assessed with the minimum value being 1 and maximum value being 5. The total scare has a minimum value of 1 and maximum value of 15 with higher scores indicating greater satisfaction. The scores are obtained by calculating the mean for each. |
6 months
|
|
Treatment Burden and Satisfaction: Motivation and Attitudes Towards Changing Health (MATCH)
Periodo de tiempo: 6 months
|
Assessed treatment burden and satisfaction using the Motivation and Attitudes towards Health Scale (MATCH), consisting of nine questions categorized into four subgroups: willingness to make changes, perceived ability to make or maintain changes, feeling changes are worthwhile, and overall mean/average of willingness, able, and worthwhile. Scores are calculated by determining the mean or average response within each category with higher scores meaning a better outcome. WILLINGNESS: minimum value is 1 and maximum value is 5. ABLE: minimum value is 1 and maximum value is 5. WORTHWHILE: minimum value is 1 and maximum value is 5. TOTAL SCALE: minimum value is 1 and maximum value is 9. |
6 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 22-000236
- 5K23DK132482-02 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .